Literature DB >> 9639418

Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia.

S M White1, E D Ball, W C Ehmann, A S Rao, D J Tweardy.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) critically affects all stages of granulopoiesis by activating a signaling cascade initiated by dimerization of its receptor (G-CSFR). Five human G-CSFR isoforms have been identified (classes I-V). A quantitative polymerase chain reaction (Q-PCR) technique was used to examine the expression of these five isoforms in normal and leukemic myeloid cells. We demonstrated that neutrophils expressed predominantly the class I isoform and low levels of class IV isoform (IV/I = 0.037 +/- 0.005). No expression of the class II, class III, or class V isoform was detected. In contrast, all AML cell lines and acute myelogenous leukemia (AML) patient samples expressed increased relative amounts of the class IV isoform (IV/I = 0.047-0.350). When compared to normal immature myeloid cells, as represented by the CD34+ fraction of adult bone marrow (ABM) cells, three of eight AML cell lines and three of six AML patient samples expressed significantly increased levels of the class IV isoform relative to class I. This suggests that the increase in the relative expression of the class IV isoform seen in a considerable portion of AML cell samples is related to their leukemic phenotype. Given the inability of the class IV G-CSFR to drive myeloid maturation, the relative increase in class IV expression in AML cells may contribute to their aberrant response to G-CSF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9639418     DOI: 10.1038/sj.leu.2401062

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition.

Authors:  H M Mehta; M Futami; T Glaubach; D W Lee; J R Andolina; Q Yang; Z Whichard; M Quinn; H F Lu; W M Kao; B Przychodzen; C A Sarkar; A Minella; J P Maciejewski; S J Corey
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

2.  A t(1;9) translocation involving CSF3R as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm.

Authors:  Jesús Gutiérrez-Abril; Iñigo Santamaría; Ana S Pitiot; Ana Gutiérrez-Fernández; Ángel Alvarez-Eguiluz; José M Vicente; Carmen Sanzo; Soledad González-Muñiz; Milagros Balbín; Xose S Puente
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

Review 3.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

4.  Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor.

Authors:  Elaine M Sloand; Agnes S M Yong; Shakti Ramkissoon; Elena Solomou; Tullia C Bruno; Sonnie Kim; Monika Fuhrer; Sachiko Kajigaya; A John Barrett; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-15       Impact factor: 11.205

5.  Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT.

Authors:  T Czerw; M Labopin; N-C Gorin; S Giebel; D Blaise; P-Y Dumas; R Foa; M Attal; N Schaap; M Michallet; C Bonmati; H Veelken; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

6.  miR-155 is associated with the leukemogenic potential of the class IV granulocyte colony-stimulating factor receptor in CD34⁺ progenitor cells.

Authors:  HaiJiao Zhang; Lilia Goudeva; Stephan Immenschuh; Axel Schambach; Julia Skokowa; Britta Eiz-Vesper; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2015-04-09       Impact factor: 6.354

7.  Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.

Authors:  Hiroto Inaba; Xueyuan Cao; Stanley Pounds; Ching-Hon Pui; Jeffrey E Rubnitz; Raul C Ribeiro; Bassem I Razzouk
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

8.  Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms.

Authors:  Borwyn A Wang; Hrishikesh M Mehta; Srinivasa R Penumutchu; Blanton S Tolbert; Chonghui Cheng; Marek Kimmel; Torsten Haferlach; Jaroslaw P Maciejewski; Seth J Corey
Journal:  Leukemia       Date:  2022-08-08       Impact factor: 12.883

Review 9.  Systems approach to phagocyte production and activation: neutrophils and monocytes.

Authors:  Hrishikesh M Mehta; Taly Glaubach; Seth Joel Corey
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Authors:  Michele S Redell; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Beverly J Lange; David J Tweardy; Soheil Meshinchi
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.